1.41
-0.14(-9.03%)
Currency In USD
| Previous Close | 1.55 |
| Open | 1.53 |
| Day High | 1.53 |
| Day Low | 1.41 |
| 52-Week High | 2.48 |
| 52-Week Low | 1.13 |
| Volume | 149,008 |
| Average Volume | 962,209 |
| Market Cap | 69.16M |
| PE | -5.64 |
| EPS | -0.25 |
| Moving Average 50 Days | 1.3 |
| Moving Average 200 Days | 1.41 |
| Change | -0.14 |
If you invested $1000 in MediciNova, Inc. (MNOV) 10 years ago, it would be worth $442.01 as of November 18, 2025 at a share price of $1.41. Whereas If you bought $1000 worth of MediciNova, Inc. (MNOV) shares 5 years ago, it would be worth $234.61 as of November 18, 2025 at a share price of $1.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
GlobeNewswire Inc.
Nov 06, 2025 11:00 PM GMT
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company h
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
GlobeNewswire Inc.
Nov 04, 2025 12:00 PM GMT
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completi
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
GlobeNewswire Inc.
Oct 30, 2025 11:00 PM GMT
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patientsLA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a b